JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265107

Human ESRP2 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ESRP2 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 11 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

ESRP2_HUMAN, Epithelial splicing regulatory protein 2, FLJ21918, FLJ22248, RBM35B, RNA binding motif protein 35A, RNA-binding motif protein 35B, RNA-binding protein 35B

1 Images
Sanger Sequencing - Human ESRP2 knockout HeLa cell line (AB265107)
  • Sanger seq

Unknown

Sanger Sequencing - Human ESRP2 knockout HeLa cell line (AB265107)

Homozygous : 11 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 11 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265107-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265107 Human ESRP2 knockout HeLa cell line", "number":"AB265107-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265107-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265107-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265107 Human ESRP2 knockout HeLa cell line", "number":"AB265107-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265107-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265107-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265107 Human ESRP2 knockout HeLa cell line", "number":"AB265107-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265107-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265107 Human ESRP2 knockout HeLa cell line", "number":"AB265107-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ESRP2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ESRP2 also known as Epithelial Splicing Regulatory Protein 2 plays a role in how RNA undergoes alternative splicing. This protein is part of the larger family of RNA-binding proteins that modulate the splicing of pre-mRNA in an epithelial cell context. ESRP2 has a molecular weight of approximately 76 kDa. It is expressed mainly in epithelial tissues including the lung kidney and intestine. Human ESRP2 encodes a protein that controls variations in mRNA which leads to different protein isoforms.
Biological function summary

ESRP2 regulates epithelial cell phenotypes by influencing the expression of genes specific to epithelial tissues. It forms a complex with ESRP1 another RNA-binding protein enhancing its ability to control RNA splicing events. The ESRP2 protein affects the alternative splicing of pre-mRNAs encoding proteins that contribute to cell adhesion motility and signaling pathways. This precise regulation of mRNA variants is critical for maintaining epithelial cellular identity and function.

Pathways

The involvement of ESRP2 in RNA splicing impacts the epithelial-mesenchymal transition (EMT) pathway. This is key in developmental processes and cancer metastasis where ESRP2 partners with ESRP1 to regulate the splice variants of genes important for EMT like FGFR2. ESRP2 affects the inclusion or exclusion of certain exons driving variation in receptor forms that have different biological outcomes influencing cell signaling and adhesion properties.

ESRP2 has significant associations with cancer progression particularly in epithelial tumors such as breast cancer and prostate cancer. Abnormal ESRP2 expression can lead to changes in EMT-related gene splicing fostering metastasis and advanced tumor states. In the context of prostate cancer ESRP2 interacts with FGFR2 and influences cancer cell invasiveness by altering specific splicing patterns highlighting its potential as a therapeutic target in cancer treatment.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com